Gastric Cancer. Malignant neoplasm of stomach
Conditions
Interventions
Intervention 1: Tablet Aspirin 81 mg (oral) Parsdarou company once daily. Intervention 2: Placebo (Control):Tablet placebo (oral) Parsdarou company once daily.
Sponsors
Ministry of Health and Medical Education
Ardabil University of Medical Sciences
National Institute for Medical Research Development
Eligibility
Sex/Gender
All
Age
35 Years to 70 Years
Inclusion criteria
Inclusion criteria: Living in the province for ten years Negative pregnancy test Willing to participate in the study Willing to provide biological specimens Willing to sign an informed consent form
Exclusion criteria
Exclusion criteria: No history of Gastric cancer History of Severe dyspepsia, peptic ulcer and GI bleeding/ perforation History of NSAID gastritis Known allergy to any of the study medications Known medical conditions that could limit life expectancy (eg. HIV/AIDS, congestive heart failure, renal failure, hepatic failure, current or prior malignancy, any other chronic disease that limits function) Prior esophageal malignancy, gastric ulcer or a gastrectomy (full or partial)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastric Cancer. Timepoint: visits at first, 12 weeks, every 4 months, 5 years and 10 years. Method of measurement: Age standardized Incidence and Mortality Rate. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Farhad Pourfarzi
Ardabil University of Medical Sciences
Outcome results
None listed